Eli Lilly's Foundayo shows up to 57% reduction in predicted 10‑year diabetes risk
On October 1, 2026 Eli Lilly announced post‑hoc analyses of its Phase 3 ATTAIN‑1 trial of the oral GLP‑1 agonist Foundayo. The study of 3,127 adults with obesity or overweight found that the drug reduced the predicted 10‑year risk of type 2 diabetes by 45%‑57% and cardiovascular risk by 13%‑18% across three dose levels over 72 weeks. The highest dose (17.2 mg) achieved a 57% diabetes risk reduction and an 18% cardiovascular risk reduction versus placebo.
Why it matters
The announcement moved LLY shares to $1,150.94, a 0.70% decline, indicating investors are weighing the potential long‑term benefit against the fact that the results are model‑based projections, not actual event outcomes.
Key facts
- 1Post‑hoc analyses of ATTAIN‑1 showed predicted 10‑year type 2 diabetes risk reductions of 45%, 50% and 57% for 5.5 mg, 9 mg and 17.2 mg doses versus placebo. rttnews.com
- 2Predicted 10‑year cardiovascular disease risk reductions were 13%, 15% and 18% for the same three doses. rttnews.com
- 3The ATTAIN‑1 trial enrolled 3,127 adults with obesity or overweight and at least one weight‑related condition. rttnews.com
- 4Participants received treatment for 72 weeks. rttnews.com
- 5At the 17.2 mg dose, predicted cardiovascular risk fell by 1.0 percentage point versus a 0.6 point increase with placebo. rttnews.com
- 6Lilly shares were trading at $1,150.94, down 0.70% after the release. rttnews.com
Summary written by AlphAI from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.